Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both ...

Researchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

A New Pacemaker Algorithm for the Treatment of Atrial Fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT) Electrophysiologic Characteristics of the Spontaneous Onset and ...

Atrial fibrillation (AF) and chronic heart failure (CHF) are two major and even growing cardiovascular conditions that often coexist. However, few data are available to guide treatment of AF in ...

As an academic cardiologist, I cherish our combined mission of providing outstanding care to patients, advancing care through research and educating the next generation.

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

Saint Francis treated its first patient with pulsed-field ablation, which delivers pulsed electric fields to tissue to treat ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...